Technology

Organizations should focus just as much of their attention on securing the actual medical devices they produce as the network they depend on, writes Chris Souza.

Clinical trials for precision therapies will require a healthy dose of education, collaboration, and data-driven decision-making from everyone involved in the process―not to mention a dedication to digital technology. Justin Grossman reports.

The digitization of healthcare is paving the way to accelerate drug development in the industry, and the FDA is doing its best to support industry.

Creating a culture of analytics will help you get the most out of your marketing efforts, writes Justin Grossman.

Jean Drouin M.D., CEO of Clarify Health Solutions, gives Pharm Exec his perspective on how biopharmaceutical companies are faring in the use of AI and machine learning

Applying game mechanics to healthcare marketing efforts has significant potential to ensure that patients are activated, educated and engaged throughout the duration of their care, which could drive business impact and improve patient outcomes.

Loetitia Jabri considers the broader implications as healthcare providers embraces new digital connectivity options as part of the Medicine 2.0 era.

Information gaps between manufacturing and regulatory, between ERP and RIM systems, are preventing all the practical and strategic benefits of data-based collaboration, writes Catherine Gambert.

Event-hopping from big biz to high tech leaves same takeaway: Adaptive leadership-not innovation-is key to future synergy.

Tim Willis and Oliver Wack outline the role of alternative data in supply chain risk management, and the ancillary benefits that come from adopting such technology.

Rick Krohn talks to Pharm Exec about the pharma applications of one of tech’s hottest solutions – blockchain.

Drug discovery to development through commercialization.

Pharm Exec’s annual look at what lies ahead for the biopharma industry in the coming months examines eight key trends that are seemingly at tipping points in their evolution and poised to shape the life sciences landscape in 2019.

Pharma companies are increasingly expanding their portfolios into digital health solutions. To find the right partners, there are several key considerations that inform their evaluation and selection.

Leaders at Novartis share how the big pharma is laying the foundations for a potential new operating model as a "medicines and data science company."

As part of its digital transformation, last year Novartis recruited Raj Patil, as Head of Data Strategy, and Shahram Ebadollahi as Head of Data Science and Advanced Analytics. Here they talk to Pharm Exec about the task that lies ahead.

Andre Heeg, Sandor's new Head of Digital, tells Pharm Exec about his digital vision for the company.

Ashley Slavic details how Veeva Systems prepared for the EU data protection regulation, and what others can learn from the experience

Pharm Exec speaks to Mark Lambrecht, Director of the Health and Life Sciences Global Practice at SAS, about the growing role of big data analytics in pharma and how the industry is evolving to keep pace with it.

Almost a year and a half later, key understandings have emerged to help companies better combat future data-breach attempts.

Sonalee Agarwal, head of value and evidence strategy for Alnylam, talks with Pharm Exec about the role of real-world evidence in the rare and ultra-rare disease space.

In pharma, there may be hope that companies' and the industry's ability to adapt to change may finally be catching up to the pace of new and intelligent uses of technology and clinical data.

How artificial intelligence, wearable devices, and translational informatics are changing healthcare.

Pharma companies now need to identify areas where AI can be applied to the digital initiatives of every pharmaceutical marketer as they strive to reach physicians with precision and usefulness, writes Gaurav Kapoor.

Keshia Vaughn looks at how machine learning can transform commercial planning and outlines what teams will need to deploy it effectively.

Emil Eifrem examines how life science researchers at Munich’s German Center for Diabetes Research are uncovering insights in their data with a new way of working with complex data

Although it is unlikely that mock demonstrators will be seen at any drug information or regulatory conferences, pharmacovigilance software is indeed having its “Salesforce” moment.

The next generation of supply chain shows an increasing need for blockchain technology.

As pharm execs look to real-world data to aid in translational research and close the gap from traditional clinical trials to real-world efficacy, there are three foundational pillars to build from. Bill Fox reports.

AI has become ubiquitous in all industries, including life sciences. But is also attracting some concerns – particularly around job losses, ethics, and more broadly, how successful it really is, writes Steve Arlington.